Dat Do, MD
Interventional Cardiology · Modesto, CANPI 1962508325
Payments from drug & device makers
Across 641 payments — averaging $31.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Johnson & Johnson$2K
- Abiomed$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Novo Nordisk$1K
- Medtronic$941
- plus $7K from 31 others
What the payments were for
- Food & beverage$19,73299%
- Education$1631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 122 | $4,529 |
| Johnson & Johnson | 97 | $2,053 |
| Abiomed | 26 | $1,943 |
| E.r. Squibb & Sons, L.L.C. | 79 | $1,682 |
| Novo Nordisk | 45 | $1,392 |
| Medtronic(2 entities) | 40 | $941 |
| Amgen | 37 | $917 |
| Boehringer Ingelheim | 25 | $761 |
| AstraZeneca | 15 | $584 |
| Bayer | 27 | $537 |
| Shockwave Medical, Inc | 9 | $498 |
| Boston Scientific | 11 | $490 |
| Novartis | 19 | $417 |
| Biotronik Inc. | 5 | $381 |
| Sanofi-aventis U.S. LLC | 12 | $337 |
| Edwards Lifesciences | 9 | $327 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $277 |
| Cardiovascular Systems Inc. | 7 | $239 |
| Merck | 8 | $217 |
| Atricure, Inc. | 3 | $176 |
| Akcea Therapeutics, Inc. | 3 | $152 |
| Regeneron Healthcare Solutions, Inc. | 7 | $132 |
| Actelion Pharmaceuticals US, Inc. | 1 | $118 |
| Lilly USA, LLC | 3 | $115 |
| Cook Medical LLC | 1 | $108 |
| Vifor Pharma, Inc. | 1 | $99 |
| Pfizer | 6 | $92 |
| Astellas Pharma US Inc | 1 | $92 |
| Esperion Therapeutics, Inc. | 4 | $78 |
| Alnylam Pharmaceuticals Inc. | 4 | $64 |
| Lexicon Pharmaceuticals, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $31 |
| Heartflow, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GALLANT$946
- Impella$837
- XARELTO$480
- JOT DX$456
- Wegovy$346
- AVEIR$307
- FARXIGA$260
- JARDIANCE$243
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$210
- Ozempic$209
- Edwards SAPIEN 3 Transcatheter Heart Valve$172
- BioMonitor$141
- AMVIA EDGE$141
- PAMIRA$141
- AVVIGO Guidance System$139
- ATRICLIP LAA EXCLUSION SYSTEM$137
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$137
- SYNERGY ABLATION SYSTEM$137
- Vascular Lithotripsy$137
- Kerendia$125
How this compares
$19,895 in reported general payments places this provider in the 65th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 389 | $481,138 |
| XareltoRivaroxaban | 166 | $207,319 |
| AdempasRiociguat | 12 | $154,602 |
| BrilintaTicagrelor | 134 | $141,600 |
| JardianceEmpagliflozin | 91 | $103,788 |
| EntrestoSacubitril/Valsartan | 51 | $55,242 |
| FarxigaDapagliflozin Propanediol | 35 | $37,708 |
| RybelsusSemaglutide | 25 | $31,956 |
| OzempicSemaglutide | 16 | $29,821 |
| Repatha SureclickEvolocumab | 25 | $28,610 |
| VascepaIcosapent Ethyl | 15 | $11,608 |
| Dofetilide | 20 | $9,613 |
| Ranolazine ErRanolazine | 69 | $9,524 |
| Atorvastatin Calcium | 778 | $7,767 |
| Icosapent Ethyl | 17 | $6,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $92 | $481,138389 claims |
| Johnson & JohnsonXarelto | $2,053 | $207,319166 claims |
| AstraZenecaBrilinta, Farxiga | $584 | $179,308169 claims |
| BayerAdempas | $537 | $154,60212 claims |
| Boehringer IngelheimJardiance | $761 | $103,78891 claims |
| Novo NordiskRybelsus, Ozempic | $1,392 | $61,77741 claims |
| NovartisEntresto | $417 | $55,24251 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Modesto
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
- Saibal KarThousand Oaks$5.4M
- Mehrdad ArianiNorthridge$5M
- Frederick St GoarMountain View$4.2M
- Sammy ElmariahSan Francisco$4.2M
- William FearonStanford$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.